Literature DB >> 7420267

Pharmacokinetics of intravenously administered bumetanide in man.

P J Pentikäinen, P J Neuvonen, M Kekki, A Penttilä.   

Abstract

Disposition of [14C]bumetanide administered intravenously to four healthy volunteers could be described by a triexponential equation. The mean half-lives associated with each exponent were 5.9 min, 46 min, and 3.1 hr, respectively. The largest fraction of dose was eliminated during the second phase; only 17% was eliminated during the last phase. The total plasma clearance averaged 228 ml/min, with renal clearance about one-half of this value. The recovery of unchanged bumetanide in urine over 2 days was 47% of the dose, while the total recovery of radioactivity in urine averaged 82% of dose. In plasma 93% of bumetanide was bound to proteins. Thus bumetanide is rapidly eliminated by both renal and nonrenal mechanisms. The elimination kinetics resembled those described for furosemide.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7420267     DOI: 10.1007/bf01059643

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  14 in total

1.  Bumetanide--acute and long term studies of a new high potency diuretic.

Authors:  W R Murdoch; W H Auld
Journal:  Postgrad Med J       Date:  1975-01       Impact factor: 2.401

2.  Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide.

Authors:  D L Davies; A F Lant; N R Millard; A J Smith; J W Ward; G M Wilson
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

3.  Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.

Authors:  K H Olesen; B Sigurd; E Steiness; A Leth
Journal:  Acta Med Scand       Date:  1973 Jan-Feb

4.  Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure.

Authors:  F Andreasen; P Jakobsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-07

5.  Pharmacokinetics of furosemide in advanced renal failure.

Authors:  C M Huang; A J Atkinson; M Levin; N W Levin; A Quintanilla
Journal:  Clin Pharmacol Ther       Date:  1974-10       Impact factor: 6.875

6.  GLC determination and urinary recovery of bumetanide in healthy volunteers.

Authors:  P W Feit; K Roholt; H Sorensen
Journal:  J Pharm Sci       Date:  1973-03       Impact factor: 3.534

7.  Absorption and excretion of furosemide-S35 in human subjects.

Authors:  B Calesnick; J A Christensen; M Richter
Journal:  Proc Soc Exp Biol Med       Date:  1966-10

8.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

9.  Bumetanide and frusemide: a comparison of dose-response curves in healthy men.

Authors:  L E Ramsay; G T McInnes; J Hettiarachchi; J Shelton; P Scott
Journal:  Br J Clin Pharmacol       Date:  1978-03       Impact factor: 4.335

10.  Bumetanide: potent new "loop" diuretic.

Authors:  M J Asbury; P B Gatenby; S O'Sullivan; E Bourke
Journal:  Br Med J       Date:  1972-01-22
View more
  10 in total

1.  Individualization of a pharmacokinetic model by fractional and nonlinear fit improvement.

Authors:  Jovan K Popović; Mihalj Poša; Kosta J Popović; Dušica J Popović; Nataša Milošević; Vesna Tepavčević
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-05-23       Impact factor: 2.441

2.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

Review 3.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

4.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.

Authors:  W R Gillespie; P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1985-08

5.  The pharmacokinetics and pharmacodynamics of bumetanide in normal subjects.

Authors:  L A Marcantonio; W H Auld; G G Skellern; C A Howes; W R Murdoch; R Purohit
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

6.  Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments.

Authors:  S H Lee; M G Lee; N D Kim
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

7.  The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.

Authors:  L A Marcantonio; W H Auld; W R Murdoch; R Purohit; G G Skellern; C A Howes
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

8.  Metabolism of the diuretic bumetanide in healthy subjects and patients with renal impairment.

Authors:  M R Howlett; G G Skellern; W H Auld; W R Murdoch
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 9.  Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  A Ward; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

Review 10.  Bumetanide Therapeutic Effect in Children and Adolescents With Autism Spectrum Disorder: A Review Study.

Authors:  Raheleh Mollajani; Mohamad Taghi Joghataei; Mehdi Tehrani-Doost
Journal:  Basic Clin Neurosci       Date:  2019-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.